Document:

Exhibit 10.13

 

	
DATED
    	
2015
    

 

STRONGBRIDGE BIOPHARMA PLC

 

AND

 

THE DIRECTORS, SECRETARY AND OFFICERS OF STRONGBRIDGE BIOPHARMA PLC

 

 

 

DEED OF INDEMNIFICATION

 

 

 

 

DEED OF INDEMNIFICATION

 

THIS DEED OF INDEMNIFICATION (this “Deed”), dated as of  · 2015 , is made by and between Strongbridge Biopharma plc, an Irish public limited company, and the Directors and Officers of Strongbridge Biopharma plc (the “Indemnitee”).

 

WHEREAS, it is essential to Strongbridge Biopharma plc to retain and attract as directors, secretary and officers the most capable persons available;

 

WHEREAS, the Indemnitee is a director, secretary or officer of Strongbridge Biopharma plc;

 

WHEREAS, each of Strongbridge Biopharma plc and the Indemnitee recognize the increased risk of litigation and other claims currently being asserted against directors and officers of companies;

 

WHEREAS, in recognition of the Indemnitee’s need for (i) substantial protection against personal liability, (ii) specific contractual assurance that such protection will be available to the Indemnitee (regardless of, among other things, any amendment to or revocation of Strongbridge Biopharma plc’s Constitution or any change in the composition of Strongbridge Biopharma plc’s Board of Directors or acquisition transaction relating to Strongbridge Biopharma plc), Strongbridge Biopharma plc wishes to provide in this Deed for the indemnification by Strongbridge Biopharma plc of the Indemnitee as set forth in this Deed, and, to the extent insurance is maintained, to provide for the continued coverage of the Indemnitee under Strongbridge Biopharma plc’s directors’ and officers’ liability insurance policies as set forth in this Deed;

 

NOW, THEREFORE, in consideration of the above premises and of the Indemnitee continuing to serve Strongbridge Biopharma plc directly and intending to be legally bound hereby, the parties agree as follows:

 

1.                                      Certain Definitions

 

1.1                               “Affiliate” means any corporation or other person or entity that directly, or indirectly through one or more intermediaries, controls or is controlled by, or is under common control with, the person specified.

 

1.2                               “Board” means the Board of Directors of Strongbridge Biopharma plc.

 

1.3                               “Change in Control” shall be deemed to have occurred if:

 

(a)                                 any “person,” as such term is used in Sections 3(a)(9) and 13(d) of the Exchange Act, becomes a “beneficial owner,” as such term is used in Rule 13d-3 promulgated under the Exchange Act, of 50% or more of the Voting Shares (as defined below) of Strongbridge Biopharma plc;

 

(b)                                 the majority of the Board consists of individuals other than Incumbent Directors, which term means the members of the Board as of the execution hereof, provided that any person becoming a director subsequent to such time whose election or nomination for election was supported by three-quarters of the directors who immediately prior to such election or nomination for election comprised the Incumbent Directors shall be considered to be an Incumbent Director;

 

(c)                                  Strongbridge Biopharma plc adopts any plan of liquidation providing for the distribution of all or substantially all of its assets;

 

 

(d)                                 all or substantially all of the assets or business of Strongbridge Biopharma plc is disposed of pursuant to a merger, consolidation or other transaction (unless the shareholders of Strongbridge Biopharma plc immediately prior to such a merger, consolidation or other transaction beneficially own, directly or indirectly, in substantially the same proportion as they owned the Voting Shares of Strongbridge Biopharma plc, all of the Voting Shares or other ownership interests of the entity or entities, if any, that succeed to the business of Strongbridge Biopharma plc); or

 

(e)                                  Strongbridge Biopharma plc combines with another company and is the surviving entity but, immediately after the combination, the shareholders of Strongbridge Biopharma plc immediately prior to the combination hold, directly or indirectly, 50% or less of the Voting Shares of the combined company (there being excluded from the number of shares held by such shareholders, but not from the Voting Shares of the combined company, any shares received by Affiliates of such other company in exchange for shares of such other company), provided, however, that any occurrence that would, in the absence of this proviso, otherwise constitute a Change in Control pursuant to any of clause (i), (iii), (iv) or (v) above, shall not constitute a Change in Control if such occurrence is approved by a majority of the directors on the Board who were directors immediately prior to such occurrence.

 

1.4                               “Enterprise” means Strongbridge Biopharma plc and any other corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise of which the Indemnitee is or was serving at the request of Strongbridge Biopharma plc as a director, officer, secretary, trustee, general partner, managing member, fiduciary, board of directors’ committee member, employee or agent.

 

1.5                               “Expenses” means any expense, liability, or loss, including legal fees, judgments, fines, amounts paid or to be paid in settlement, any interest, assessments, or other charges imposed thereon, any state, local, or foreign taxes imposed as a result of the actual or deemed receipt of any payments under this Deed, and all other costs and obligations, paid or incurred in connection with investigating, defending, prosecuting (subject to Section 2(b)), being a witness in, participating in (including on appeal), or preparing for any of the foregoing in, any Proceeding relating to any Indemnifiable Event. Expenses also shall include Expenses incurred in connection with any appeal resulting from any Proceeding, including without limitation the premium, security for, and other costs relating to any cost bond, supersedeas bond, or other appeal bond or its equivalent.

 

1.6                               “Indemnifiable Event” means any event or occurrence that takes place either prior to or after the execution of this Deed, related to the fact that the Indemnitee is or was a director, officer, secretary or employee of Strongbridge Biopharma plc, or while a director or secretary of Strongbridge Biopharma plc is or was serving at the request of Strongbridge Biopharma plc as a director, officer, secretary, employee, trustee, agent, or fiduciary of another foreign or domestic corporation, partnership, limited liability company, joint venture, employee benefit plan, trust, or other Enterprise, or related to anything done or not done by the Indemnitee in any such capacity, whether or not the basis of the Proceeding is alleged action in an official capacity as a director, officer, secretary, employee, trustee, agent, or fiduciary or in any other capacity while serving as a director, officer, secretary, employee, trustee, agent, or fiduciary.

 

1.7                               “Independent Counsel” has the meaning specified in Section 3.

 

 

1.8                               “Proceeding” means any threatened, pending, or completed action, suit, or proceeding or any alternative dispute resolution mechanism (including an action by or in the right of Strongbridge Biopharma plc), or any inquiry, hearing, or investigation, whether conducted by Strongbridge Biopharma plc or any other party, that the Indemnitee in good faith believes might lead to the institution of any such action, suit, or proceeding, whether civil, criminal, administrative, investigative, or other.

 

1.9                               “Reviewing Party” means the meaning specified in Section 3.

 

1.10                        “Voting Shares” means shares of any class or classes having general voting power under ordinary circumstances, in the absence of contingencies, to elect the directors (or similar function) of an Enterprise.

 

2.                                      Agreement to Indemnify

 

2.1                               General Agreement

 

In the event the Indemnitee was, is, or becomes a party to or witness or other participant in, or is threatened to be made a party to or witness or other participant in, a Proceeding by reason of (or arising in part out of) an Indemnifiable Event, Strongbridge Biopharma plc shall indemnify the Indemnitee from and against any and all Expenses to the fullest extent permitted by law, as the same exists or may hereafter be amended or interpreted (but in the case of any such amendment or interpretation, only to the extent that such amendment or interpretation permits Strongbridge Biopharma plc to provide broader indemnification rights than were permitted prior thereto). For the purposes of this Deed; the meaning of the phrase “to the fullest extent permitted by law” shall include, but not be limited to:’ (i) to the fullest extent permitted by the provisions of Irish law and/or the Constitution of Strongbridge Biopharma plc that authorise, permit or contemplate indemnification by agreement, court action or corresponding provisions of any amendment to or replacement of such provisions; and (ii) to the fullest extent authorized or permitted by any amendments to or replacements of Irish law and/or the Constitution of Strongbridge Biopharma plc adopted after the date of this Deed that increase the extent to which a company may indemnify its directors, secretary or officers.

 

2.2                               Initiation of Proceeding

 

Notwithstanding anything in this Deed to the contrary, the Indemnitee shall not be entitled to indemnification pursuant to this Deed in connection with any Proceeding initiated by the Indemnitee against Strongbridge Biopharma plc or any of its subsidiaries or any director, officer or employee of Strongbridge Biopharma plc or any of its subsidiaries unless (i) Strongbridge Biopharma plc has joined in or the Board has consented to the initiation of such Proceeding; (ii) the Proceeding is one to enforce indemnification rights under Section 4; or (iii) the Proceeding is instituted after a Change in Control and Independent Counsel has approved its initiation.

 

2.3                               Mandatory Indemnification

 

Notwithstanding any other provision of this Deed, to the extent that the Indemnitee has been successful on the merits or otherwise in defence of any Proceeding relating in whole or in part to an Indemnifiable Event or in defence of any issue or matter therein, the Indemnitee shall be indemnified by Strongbridge Biopharma plc hereunder against all Expenses incurred in connection therewith.

 

 

2.4                               Partial Indemnification

 

If the Indemnitee is entitled under any provision of this Deed to indemnification by Strongbridge Biopharma plc for some or a portion of Expenses, but not, however, for the total amount thereof, Strongbridge Biopharma plc shall nevertheless indemnify the Indemnitee for the portion thereof to which the Indemnitee is entitled.

 

2.5                               Prohibited Indemnification

 

No indemnification pursuant to this Deed shall be paid by Strongbridge Biopharma plc:

 

(a)                                 on account of any Proceeding in which a final and non-appealable judgment is rendered against the Indemnitee for an accounting of profits made from the purchase or sale by the Indemnitee of securities of Strongbridge Biopharma plc pursuant to the provisions of Section 16(b) of the Exchange Act or similar provisions of any federal, state or local laws;

 

(b)                                 if a court of competent jurisdiction by a final and non-appealable judgment, shall determine that such indemnification is not permitted under applicable law;

 

(c)                                  on account of any Proceeding relating to an Indemnifiable Event as to which the Indemnitee has been convicted of a crime constituting a felony under the laws of the jurisdiction where the criminal action had been brought (or, where a jurisdiction does not classify any crime as a felony, a crime for which the Indemnitee is sentenced to death or imprisonment for a term exceeding one year); or

 

(d)                                 on account of any Proceeding brought by Strongbridge Biopharma plc or any of its subsidiaries against the Indemnitee.

 

3.                                      Reviewing Party: Exhaustion of Remedies

 

3.1                               Prior to any Change in Control, the reviewing party (the “Reviewing Party”) shall be any appropriate person or body consisting of a member or members of the Board or any other person or body appointed by the Board who is not a party to the particular Proceeding with respect to which the Indemnitee is seeking indemnification; after a Change in Control, the Independent Counsel referred to below shall become the Reviewing Party. With respect to all matters arising after a Change in Control concerning the rights of Indemnitee to indemnity payments and Expense advances under this Deed or any other agreement to which Strongbridge Biopharma plc or any of its Affiliates is a party or under applicable law, Strongbridge Biopharma plc’s Constitution or the certificate of incorporation now or hereafter in effect relating to indemnification for Indemnifiable Events, Strongbridge Biopharma plc shall seek legal advice only from independent counsel (“Independent Counsel”) selected by Indemnitee and approved by Strongbridge Biopharma plc (which approval shall not be unreasonably withheld), and who has not otherwise performed services for Strongbridge Biopharma plc or the Indemnitee (other than in connection with indemnification matters) within the last five years. The Independent Counsel shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing Strongbridge Biopharma plc or Indemnitee in an action to determine Indemnitee’s rights under this Deed. Such counsel, among other things, shall render its written opinion to Strongbridge Biopharma plc and the Indemnitee as to whether and to what extent the Indemnitee should be permitted to be indemnified under applicable law. In doing so, the

 

 

Independent Counsel may consult with (and rely upon) counsel in any appropriate jurisdiction who would qualify as Independent Counsel (“Local Counsel”). To the fullest extent permitted by law, Strongbridge Biopharma plc agrees to pay the reasonable fees of the Independent Counsel and the Local Counsel and to indemnify fully such counsel against any and all expenses (including legal fees), claims, liabilities, loss, and damages arising out of or relating to this Deed or the engagement of Independent Counsel or the Local Counsel pursuant hereto.

 

4.                                      Indemnification Process and Appeal

 

4.1                               Indemnification Payment

 

The Indemnitee shall be entitled to indemnification of Expenses, and shall receive payment thereof, from Strongbridge Biopharma plc in accordance with this Deed as soon as practicable after Indemnitee has made written demand on Strongbridge Biopharma plc for indemnification, unless the Reviewing Party has given a written opinion to Strongbridge Biopharma plc that the Indemnitee is not entitled to indemnification under applicable law.

 

4.2                               Adjudication or Arbitration

 

(a)                                 Regardless of any action by the Reviewing Party, if the Indemnitee has not received full indemnification to which the Indemnitee is entitled hereunder within thirty days after making a demand or request in accordance with Section 4.1 (a “Nonpayment”), the Indemnitee shall have the right to enforce its indemnification rights under this Deed by commencing litigation in any court located in the country of Ireland (an “Irish Court”) having subject matter jurisdiction thereof seeking an initial determination by the court or by challenging any determination by the Reviewing Party or any aspect thereof. Any determination by the Reviewing Party not challenged by Indemnitee in any such litigation shall be binding on Strongbridge Biopharma plc and the Indemnitee. The remedy provided for in this Section 4 shall be in addition to any other remedies available to Indemnitee at law or in equity. Strongbridge Biopharma plc and the Indemnitee hereby irrevocably and unconditionally (A) consent to submit to the nonexclusive jurisdiction of the Irish Court for purposes of any action or proceeding arising out of or in connection with this Deed, (B) waive any objection to the laying of venue of any such action or proceeding in the Irish Court, and (C) waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Irish Court has been brought in an improper or inconvenient forum. For the avoidance of doubt, nothing in this Deed shall limit any right the Indemnitee may have under applicable law to bring any action or proceeding in any other court.

 

(b)                                 Alternatively, in the case of a Non-payment, the Indemnitee, at his or her option, may seek an award in arbitration to be conducted by a single arbitrator pursuant to the Commercial Arbitration Rules of the American Arbitration Association.

 

(c)                                  In the event that a determination shall have been made pursuant to Section 4(a) of this Deed that the Indemnitee is not entitled to indemnification, any judicial proceeding or arbitration commenced pursuant to this Section 4(b) shall be conducted in all respects as a de novo trial, or arbitration, on the merits, and the Indemnitee shall not be prejudiced by reason of that adverse determination. In any judicial proceeding or arbitration commenced pursuant

 

 

to this Section 4.2 Strongbridge Biopharma plc shall have the burden of proving Indemnitee is not entitled to indemnification.

 

(d)                                 In the event that Indemnitee, pursuant to this Section 4.2, seeks a judicial adjudication of or an award in arbitration to enforce his or her rights under, or to recover damages for breach of, this Deed, and it is determined in said judicial adjudication or arbitration that the Indemnitee is entitled to receive all of the indemnification sought, the Indemnitee shall be entitled to recover from Strongbridge Biopharma plc, and shall be indemnified by Strongbridge Biopharma plc against, any and all Expenses actually and reasonably incurred by him in such judicial adjudication or arbitration. If it shall be determined in said judicial adjudication or arbitration that Indemnitee is entitled to receive part but not all of the indemnification sought, the Indemnitee shall be entitled to recover from Strongbridge Biopharma plc, and shall be indemnified by Strongbridge Biopharma plc against, any and all Expenses reasonably incurred by Indemnitee in connection with such judicial adjudication or arbitration.

 

4.3                               Defence to Indemnification, Burden of Proof, and Presumptions

 

(a)                                 It shall be a defence to any action brought by the Indemnitee against Strongbridge Biopharma plc to enforce this Deed that it is not permissible under applicable law for Strongbridge Biopharma plc to indemnify the Indemnitee for the amount claimed.

 

(b)                                 In connection with any action or any determination by the Reviewing Party or otherwise as to whether the Indemnitee is entitled to be indemnified hereunder, the burden of proving such a defense or determination shall be on Strongbridge Biopharma plc.

 

(c)                                  Neither the failure of the Reviewing Party to have made a determination prior to the commencement of such action by the Indemnitee that indemnification of the Indemnitee is proper under the circumstances because the Indemnitee has met the standard of conduct set forth in applicable law, nor an actual determination by the Reviewing Party that the Indemnitee had not met such applicable standard of conduct, shall, of itself, be a defence to the action or create a presumption that the Indemnitee has not met the applicable standard

 

(d)                                 For purposes of this Deed, to the fullest extent permitted by law, the termination of any claim, action, suit, or proceeding, by judgment, order, settlement (whether with or without court approval), conviction, or upon a plea of nolo contendere, or its equivalent, shall not, of itself, create a presumption that Indemnitee did not meet any particular standard of conduct or have any particular belief or that a court has determined that indemnification is not permitted by applicable law.

 

(e)                                  For purposes of any determination of good faith, the Indemnitee shall be deemed to have acted in good faith if the Indemnitee’s action is based on the records or books of account of any Enterprise, including financial statements, or on information supplied to Indemnitee by the management of such Enterprise in the course of their duties, or on the advice of legal counsel for such Enterprise or on information or records given or reports made to such Enterprise by an independent certified public accountant or by an appraiser or other expert selected by such Enterprise. The provisions of this Section 4.3(e)

 

 

shall not be deemed to be exclusive or to limit in any way the other circumstances in which the Indemnitee may be deemed or found to have met the applicable standard of conduct set forth in applicable law.

 

(f)                                   The knowledge and/or actions, or failure to act, of any other director, trustee, partner, managing member, fiduciary, officer, agent or employee of any Enterprise shall not be imputed to Indemnitee for purposes of determining any right to indemnification under this Deed.

 

(g)                                  Strongbridge Biopharma plc shall be precluded from asserting in any judicial proceeding or arbitration commenced pursuant to this Deed that the procedures or presumptions of this Deed are not valid, binding and enforceable and shall stipulate in any court or before any arbitrator that Strongbridge Biopharma plc is bound by all the provisions of this Deed.

 

5.                                      Indemnification for Expenses Incurred in Enforcing Rights.

 

In addition to the Indemnitee’s rights under Section 4.3(d) Strongbridge Biopharma plc shall indemnify the Indemnitee against any and all Expenses that are incurred by the Indemnitee in connection with any action brought by the Indemnitee:

 

(a)                                 for indemnification or advance payment of Expenses under any agreement to which Strongbridge Biopharma plc or any of its Affiliates is a party (other than this Deed) or under applicable law, Strongbridge Biopharma plc’s Constitution or hereafter in effect relating to indemnification or advance payment of Expenses for Indemnifiable Events (it being specified, for the avoidance of doubt, that this clause (a) shall not be deemed to provide the Indemnitee with a right to the indemnification or advance payment of Expenses being sought in such action) and/or

 

(b)                                 for recovery under directors’ and officers’ liability insurance policies maintained by Strongbridge Biopharma plc

 

but, in either case, only in the event that the Indemnitee ultimately is determined to be entitled to such indemnification or expense advance or insurance recovery, as the case may be.

 

6.                                      Notification and Defense of Proceeding

 

6.1                               Notice

 

Promptly after receipt by the Indemnitee of notice of the commencement of any Proceeding, Indemnitee shall, if a claim in respect thereof is to be made against Strongbridge Biopharma plc under this Deed, notify Strongbridge Biopharma of the commencement thereof; but the omission so to notify Strongbridge Biopharma plc will not relieve Strongbridge Biopharma plc from any liability that it may have to Indemnitee, except as provided in Section 6.3.

 

6.2                               Defence

 

With respect to any Proceeding as to which Indemnitee notifies Strongbridge Biopharma plc of the commencement thereof, Strongbridge Biopharma plc will be entitled to participate in the Proceeding at its own expense and except as otherwise provided below, to the extent Strongbridge Biopharma plc so wishes, it may assume the defence thereof with counsel reasonably satisfactory to the Indemnitee. After notice from Strongbridge Biopharma plc to the Indemnitee of its election to assume the defence of any Proceeding, Strongbridge Biopharma plc shall not be liable to the

 

 

Indemnitee under this Deed or otherwise for any Expenses subsequently incurred by the Indemnitee in connection with the defence of such Proceeding other than reasonable costs of investigation or as otherwise provided below. The Indemnitee shall have the right to employ legal counsel in such Proceeding, but all Expenses related thereto incurred after notice from Strongbridge Biopharma plc of its assumption of the defence shall be at the Indemnitee’s expense unless: (i) the employment of legal counsel by the Indemnitee has been authorized by Strongbridge Biopharma plc, (ii) the Indemnitee has reasonably determined that there may be a conflict of interest between the Indemnitee and Strongbridge Biopharma plc in the defence of the Proceeding, (iii) after a Change in Control, the employment of counsel by the Indemnitee has been approved by the Independent Counsel, or (iv) Strongbridge Biopharma plc shall not in fact have employed counsel to assume the defence of such Proceeding, in each of which cases all Expenses of the Proceeding shall be borne by Strongbridge Biopharma plc. Strongbridge Biopharma plc shall not be entitled to assume the defence of any Proceeding (x) brought by or on behalf of Strongbridge Biopharma plc, (y) as to which the Indemnitee shall have made the determination provided for in (ii) above or (z) after a Change in Control (it being specified, for the avoidance of doubt, that Strongbridge Biopharma plc may assume defence of any such proceeding described in this sentence with the Indemnitee’s consent, provided that any such consent shall not affect the rights of the Indemnitee under the foregoing provisions of this Section 6.2).

 

6.3                               Settlement of Claims

 

Strongbridge Biopharma plc shall not be liable to indemnify the Indemnitee under this Deed or otherwise for any amounts paid in settlement of any Proceeding effected without Strongbridge Biopharma plc’s written consent, such consent not to be unreasonably withheld; provided, however, that if a Change in Control has occurred, Strongbridge Biopharma plc shall be liable for indemnification of the Indemnitee for amounts paid in settlement if the Independent Counsel has approved the settlement. Strongbridge Biopharma plc shall not settle any Proceeding in any manner that would impose any penalty or limitation on the Indemnitee without the Indemnitee’s written consent. Strongbridge Biopharma plc shall not be liable to indemnify the Indemnitee under this Deed with regard to any judicial award if Strongbridge Biopharma plc was not given a reasonable and timely opportunity, at its expense, to participate in the defence of such action; Strongbridge Biopharma plc’s liability hereunder shall not be excused if assumption of the defense of the Proceeding by Strongbridge Biopharma plc was barred by this Deed.

 

7.                                      Establishment of Trust

 

In the event of a Change in Control Strongbridge Biopharma plc shall, upon written request by the Indemnitee, create a trust for the benefit of the Indemnitee (the “Trust”) and from time to time upon written request of the Indemnitee shall fund the Trust in an amount sufficient to satisfy any and all Expenses reasonably anticipated at the time of each such request (a) to be incurred in connection with investigating, preparing for, participating in, and/or defending any Proceeding relating to an Indemnifiable Event and (b) to be indemnifiable pursuant to this Deed. The amount or amounts to be deposited in the Trust pursuant to the foregoing funding obligation shall be determined by the Independent Counsel. The terms of the Trust shall provide that (i) the Trust shall not be revoked or the principal thereof invaded without the written consent of the Indemnitee, (ii) the Trust shall continue to be funded by Strongbridge Biopharma plc in accordance with the funding obligation set forth above, (iii) the Trustee shall promptly pay to the Indemnitee all amounts for which the Indemnitee shall be entitled to indemnification pursuant to this Deed, and (iv) all unexpended funds in the Trust shall revert to Strongbridge Biopharma plc upon a final determination by the Independent Counsel or a

 

 

court of competent jurisdiction, as the case may be, that the Indemnitee has been fully indemnified under the terms of this Deed. The trustee of the Trust (the “Trustee”) shall be chosen by the Indemnitee. Nothing in this Section 7 shall relieve Strongbridge Biopharma plc of any of its obligations under this Deed. All income earned on the assets held in the Trust shall be reported as income by Strongbridge Biopharma plc for state, local, and foreign tax purposes. Strongbridge Biopharma plc shall pay all costs of establishing and maintaining the Trust and shall indemnify the Trustee against any and all expenses (including legal fees), claims, liabilities, loss, and damages arising out of or relating to this Deed or the establishment and maintenance of the Trust.

 

8.                                      Non-Exclusivity

 

The rights of the Indemnitee hereunder shall be in addition to any other rights Indemnitee may have under Strongbridge Biopharma plc’s Constitution,  applicable law, or otherwise. To the extent that a change in applicable law (whether by statute or judicial decision) permits greater indemnification than would be afforded currently under Strongbridge Biopharma plc’s Constitution, applicable law or this Deed, it is the intent of the parties that Indemnitee enjoy by this Deed the greater benefits so afforded by such change.

 

9.                                      Liability Insurance

 

For so long as the Indemnitee has indemnification rights hereunder, Strongbridge Biopharma plc shall maintain an insurance policy or policies providing general and/or directors’ and officers’ liability insurance covering the Indemnitee, in accordance with the terms of such policy or policies, to the maximum extent of the coverage available for any director, officer, secretary or employee, as applicable, of Strongbridge Biopharma plc, provided and to the extent that such insurance is available on a commercially reasonable basis.

 

10.                               Exclusions

 

In addition to and notwithstanding any other provision of this Deed to the contrary, Strongbridge Biopharma plc shall not be obligated under this Deed to make any payment pursuant to this Deed for which payment is expressly prohibited by law (including, with respect to any director or secretary of Strongbridge Biopharma plc, in respect of any liability expressly prohibited from being indemnified pursuant to section 235 of the Irish Companies Act 2014 (including any successor provisions, “Section 235”), but (i) in no way limiting any rights under section 233 of the Irish Companies Act 2014, and (ii) to the extent any such limitations or prescriptions are amended or determined by a court of a competent jurisdiction to be void or inapplicable, or relief to the contrary is granted, then the Indemnitee shall receive the greatest rights then available under law.

 

11.                               Continuation of Contractual Indemnity or Period of Limitations

 

All agreements and obligations of Strongbridge Biopharma plc contained herein shall continue for so long as the Indemnitee shall be subject to, or involved in, any proceeding for which indemnification is provided pursuant to this Deed. Notwithstanding the foregoing, no legal action shall be brought and no cause of action shall be as inserted by or on behalf of Strongbridge Biopharma plc or any Affiliate of Strongbridge Biopharma plc against the Indemnitee, the Indemnitee’s spouse, heirs, executors, or personal or legal representatives after the expiration of two years from the date of accrual of such cause of action, or such longer period as may be required by the laws of Ireland under the circumstances. Any claim or cause of action of Strongbridge Biopharma plc or its Affiliate shall be extinguished and deemed released unless asserted by the timely filing and notice of a legal action within such period; provided, however, that if any shorter period of limitations is otherwise applicable to any such cause of action, the shorter period shall govern.

 

 

12.                               Amendment of this Deed

 

No supplement, modification, or amendment of this Deed shall be binding unless executed in writing by each of the parties hereto. No waiver of any of the provisions of this Deed shall be binding unless in the form of writing signed by the party against whom enforcement of the waiver is sought, and no such waiver shall operate as a continuing waiver. Except as specifically provided herein, no failure to exercise or any delay in exercising any right or remedy hereunder shall constitute a waiver thereof.

 

13.                               Subrogation

 

In the event of payment under this Deed, Strongbridge Biopharma plc shall be subrogated to the extent of such payment to all of the rights of recovery of the Indemnitee, who shall execute all papers required and shall do everything that may be necessary to secure such rights, including the execution of such documents necessary to enable Strongbridge Biopharma plc effectively to bring suit to enforce such rights.

 

14.                               No Duplication of Payments

 

Strongbridge Biopharma plc shall not be liable under this Deed to make any payment in connection with any claim made by the Indemnitee to the extent the Indemnitee has otherwise received payment (under any insurance policy, Strongbridge Biopharma plc’s Constitution, or otherwise) of the amounts otherwise indemnifiable hereunder.

 

15.                               Obligations of Strongbridge Biopharma plc

 

In the event a Proceeding results in a judgment in the Indemnitee’s favour or otherwise is disposed of in a manner that allows Strongbridge Biopharma plc to indemnify the Indemnitee in connection with such Proceeding under the Constitution of Strongbridge Biopharma plc as then in effect, Strongbridge Biopharma plc will provide such indemnification to the Indemnitee in connection with such Proceeding.

 

16.                               Binding Effect

 

This Agreement shall be binding upon and inure to the benefit of and be enforceable by the parties hereto and their respective successors (including any direct or indirect successor by purchase, merger, consolidation, or otherwise to all or substantially all of the business and/or assets of Strongbridge Biopharma plc), assigns, spouses, heirs, and personal and legal representatives. Strongbridge Biopharma plc shall require and cause any successor thereof (whether direct or indirect by purchase, merger, consolidation, or otherwise) to all, substantially all, or a substantial part, of the business and/or assets of Strongbridge Biopharma plc, by written agreement in form and substance satisfactory to Indemnitee, expressly to assume and agree to perform this Deed in the same manner and to the same extent that Strongbridge Biopharma plc would be required to perform if no such succession had taken place. The indemnification provided under this Deed shall continue as to the Indemnitee for any action taken or not taken while serving in an indemnified capacity pertaining to an Indemnifiable Event even though he may have ceased to serve in such capacity at the time of any Proceeding or is deceased and shall inure to the benefit of the heirs, executors, administrators, legatees and assigns of such a person.

 

17.                               Severability

 

If any provision (or portion thereof) of this Deed shall be held by a court of competent jurisdiction to be invalid, void, or otherwise unenforceable, the remaining provisions shall remain enforceable to the fullest extent permitted by law. Furthermore, to the fullest extent possible, the provisions of this Deed (including, without limitation, each portion of this Deed containing any provision held to be invalid, void, or otherwise unenforceable that is not itself invalid, void or unenforceable) shall be construed so as to give effect to the intent manifested by the provision held invalid, void or unenforceable.

 

 

18.                               Governing Law

 

This Agreement shall be governed by and construed and enforced in accordance with the laws of Ireland applicable to contracts made and to be performed in such State without giving effects to its principles of conflicts of laws.

 

19.                               Notices

 

All notices, demands, and other communications required or permitted hereunder shall be made in writing and shall be deem to have been duly given if delivered by hand, against receipt, or mailed, postage prepaid, certified or registered mail, return receipt requested, and address to:

 

Strongbridge Biopharma plc at: [ · ]

 

And to Indemnitee at: [insert address of Indemnitee]

 

Notice of change of address shall be effective only when given in accordance with this Section. All notices complying with this Section shall be deemed to have been received on the date of hand delivery or on the third business day after mailing.

 

20.                               Counterparts

 

This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

 

12

 

IN WITNESS WHEREOF the parties have executed this Deed of Indemnification as a deed with the intention that it be delivered on the date first written above.

 

 

GIVEN under the Common Seal of

STRONGBRIDGE BIOPHARMA PLC

and DELIVERED as a DEED:

 

 

The Indemnitee:

 

	
SIGNED AND DELIVERED as a   deed
    	
 
    
	
by [ · ] [insert name of indemnitee]
    	
 
    
	
in the presence of:
    	
 
    
	
 
    	
 
    
	
(Signature of Witness):
    	
 
    
	
 
    	
 
    
	
(Name of Witness):
    	
 
    
	
 
    	
 
    
	
(Address of Witness):
    	
 
    
	
 
    	
 
    
	
(Occupation of Witness):
    	
 
    

 

13Exhibit 4.1

 

	

    	
SPECIMEN   SPECIMEN NUMBER SEE REVERSE FOR CERTAIN DEFINITIONS INCORPORATED UNDER THE   LAWS OF THE STATE OF DELAWARE CoMMonsToCK This CerTifies ThaT: SPECIMEN is   The owner of FULLY PAID AND NON-ASSESSABLE SHARES OF THE COMMON STOCK, PAR   VALUE $.00001 EACH OF aClaris TherapeuTiCs, inC. transferable on the books of   the Corporation in person or by attorney upon surrender of this certificate   duly endorsed or assigned. This certificate and the shares represented hereby   are subject to the laws of the State of Delaware, and to the Certificate of   Incorporation and Bylaws of the Corporation, as now or hereafter amended.   This certificate is not valid until countersigned by the Transfer Agent.   WITNESS the facsimile seal of the Corporation and the facsimile signatures of   its duly authorized officers. COUNTERSIGNED: BROADRIDGE CORPORATE ISSUER   SOLUTIONS, INC. 1717 ARCH ST., STE. 1300, PHILADELPHIA, PA 19103 TRANSFER   AGENT DATED: BY: AUTHORIZED SIGNATURE SECRETARY PRESIDENT CUSIP 00461U 10 5   SHARES
    

 

 

	

    	
The following   abbreviations, when used in the inscription on the face of this certificate,   shall be construed as though they were written out in full according to   applicable laws or regulations: TEN COM - as tenants in common TEN ENT - as   tenants by the entireties UNIF GIFT MIN ACT -   ....................Custodian.................... (Cust) (Minor) JT TEN - as   joint tenants with right of survivorship and not as tenants in common under   Uniform Gifts to Minors Act ...................................................   (State) Additional abbreviations may also be used though not in the above   list. For Value Received, hereby sell, assign and transfer unto PLEASE INSERT   SOCIAL SECURITY OR OTHER IDENTIFYING NUMBER OF ASSIGNEE (PLEASE PRINT OR TYPE   NAME AND ADDRESS, INCLUDING ZIP CODE, OF ASSIGNEE) Shares of the stock   represented by the within Certificate, and do hereby irrevocably constitute   and appoint Attorney to transfer the said stock on the books of the within   named Corporation with full power of substitution in the premises. Dated   NOTICE: THE SIGNATURE TO THIS ASSIGNMENT MUST CORRESPOND WITH THE NAME AS   WRITTEN UPON THE FACE OF THE CERTIFICATE IN EVERY PARTICULAR, WITHOUT   ALTERATION OR ENLARGEMENT OR ANY CHANGE WHATSOEVER. Signature(s) Guaranteed   By The Signature(s) must be guaranteed by an eligible guarantor institution   (Banks, Stockbrokers, Savings and Loan Associations and Credit Unions with   membership in an approved Signature Guarantee Medallion Program), pursuant to   SEC Rule 17Ad-15. THE CORPORATION WILL FURNISH TO ANY STOCKHOLDER, UPON   REQUEST AND WITHOUT CHARGE, A FULL STATEMENT OF THE DESIGNATIONS, RELATIVE   RIGHTS, PREFERENCES AND LIMITATIONS OF THE SHARES OF EACH CLASS AND SERIES   AUTHORIZED TO BE ISSUED, SO FAR AS THE SAME HAVE BEEN DETERMINED, AND OF THE   AUTHORITY, IF ANY, OF THE BOARD TO DIVIDE THE SHARES INTO CLASSES OR SERIES   AND TO DETERMINE AND CHANGE THE RELATIVE RIGHTS, PREFERENCES AND LIMITATIONS   OF ANY CLASS OR SERIES. SUCH REQUEST MAY BE MADE TO THE SECRETARY OF THE   CORPORATION OR TO THE TRANSFER AGENT NAMED ON THIS CERTIFICATE. COLUMBIA   PRINTING SERVICES, LLC - www.stockinformation.com

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00249-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00249-of-00352.parquet"}]]